Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Canaccord Genuity

Critical Insights From Ulta Beauty Analyst Ratings: What You Need To Know

Ratings for Ulta Beauty (NASDAQ:ULTA) were provided by 28 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

Benzinga

Lululemon Athletica To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga

Peeling Back The Layers: Exploring Atlassian Through Analyst Insights

In the latest quarter, 21 analysts provided ratings for Atlassian (NASDAQ:TEAM), showcasing a mix of bullish and bearish perspectives.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

The Latest Analyst Ratings For Progyny

Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Progyny (NASDAQ:PGNY) in the last three months.

Benzinga

Where Hims & Hers Health Stands With Analysts

Analysts' ratings for Hims Hers Health (NYSE:HIMS) over the last quarter vary from bullish to bearish, as provided by 10 analysts.

Benzinga

Viant Technology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

Viant Technology (NASDAQ:DSP) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

Benzinga

The Analyst Verdict: Edwards Lifesciences In The Eyes Of 17 Experts

Analysts' ratings for Edwards Lifesciences (NYSE:EW) over the last quarter vary from bullish to bearish, as provided by 17 analysts.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Urban Outfitters To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga

The Latest Analyst Ratings For Helen Of Troy

4 analysts have shared their evaluations of Helen Of Troy (NASDAQ:HELE) during the recent three months, expressing a mix of bullish and bearish perspectives.

Benzinga

Salesforce To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga

Two-Thirds Of Survey Respondents Would Not Buy A Tesla Cybertruck—Would You?

Design and pricing were the biggest turn-offs for many of those who participated in the survey conducted by global investment banking company Canaccord Genuity.

InsideEVs

Tupperware or Newell Brands: Which Is the Dumber Buy?

Tupperware’s stock is up 450% over the past month. That’s got investors in meme stocks climbing over each other to get a piece of the food storage company. While you're at it, maybe you should buy some Newell Brands stock as well.

Barchart

Company's new wearable device will help diabetics eat right, lose weight

SAN DIEGO — San Diego's Dexcom, a maker of continuous glucose monitors, laid out plans for a new wearable device coming in 2024 for people with Type 2 diabetes who don't need insulin — a move that could help bring wearable health monitors closer to the mainstream.

Tribune News Service

Tory election chief's own firm admits Britain's 'economic misery made worse' by ministers

Millionaire banker Stephen Massey has taken over the running of the Conservative Party's local election campaign. His City firm warned Britain is facing 'insipid growth' under this government

Daily Mirror

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022

Upgrades

Benzinga

Meta Platforms To $200? These Analysts Slash Price Targets On Meta Following Q3 Results

Meta Platforms, Inc. (NASDAQ: META) reported worse-than-expected Q3 EPS and issued Q4 revenue guidance with a midpoint below estimates. The company also guided FY23 expenses of $96 billion to $101 billion. Meta Platforms shares dropped 22.1% to $101.20 on Thursday.

Benzinga

This Is What Whales Are Betting On Beyond Meat

Someone with a lot of money to spend has taken a bullish stance on Beyond Meat (NASDAQ:BYND). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

This Is What Whales Are Betting On Beyond Meat

A whale with a lot of money to spend has taken a noticeably bearish stance on Beyond Meat. Looking at options history for Beyond Meat (NASDAQ:BYND) we detected 11 strange trades.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022

Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago quarter.

Benzinga

Ethereum Is 'Blue Chip Blockchain,' Could See Significant Value Boost: Canaccord Analysts

Cryptocurrency Ethereum (CRYPTO: ETH) and the smart contract ecosystem were sized up by Canaccord Genuity in a new note.

Benzinga

Salesforce Faces Price Target Cuts On Guidance Cut, Shares Slide

Salesforce Inc (NYSE: CRM) reported upbeat results for its second quarter, but lowered its annual projections.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022

Benzinga

This MicroStrategy Analyst Is Slashing Their Price Target After $1B Loss, Michael Saylor Steps Down

MicroStrategy (NYSE: MSTR) recently reported a net loss of more than $1 billion in the second quarter compared with a loss of about $299.3 million in the same period last year.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.